IBRX

2 IBRX buys, 1 buyer, 3 calendar days

2 tracked trades in ImmunityBio, Inc. (IBRX) were recorded from September 28 through September 30, 2026. Both were buys, with no sells in the provided activity. The transactions came from one distinct trader, Lisa McClain, whose latest IBRX purchase was dated September 30.

All of the tracked activity falls within 2026 Q3: two trades and two buys. That produces a uniformly positive transaction direction in this dataset, but the sample is only two purchases by one person. It therefore does not show whether buying was broad-based among multiple congressional traders or sustained over a longer period. No transaction amount information was provided, so the relative size of the two purchases cannot be compared.

6 other tickers linked to the same buyer

1 of the IBRX buyers also bought each of RIG, MSFT, NG, CACI, OLN and CAT. Because IBRX has only one tracked buyer, each overlap refers to Lisa McClain. These additional purchases span tickers outside IBRX’s Healthcare/Biotechnology classification, but the supplied facts do not include their trade dates, amounts or number of transactions beyond the stated buyer overlap.

The cross-ticker activity provides context that the IBRX purchases were not the only disclosed buys associated with this trader. It does not establish why any security was purchased or whether the trades were related.

45-day lag limits timing conclusions

45 days is the relevant potential disclosure lag for congressional trading reports, so public visibility can occur well after the transaction date. The dates above describe the reported trades, not necessarily when observers could first evaluate them. Disclosed transaction values are generally presented as ranges, and any amount estimates derived from those ranges are approximate; no such ranges were supplied here. With two trades, zero sells and one trader, conclusions about broader IBRX trading patterns remain especially limited.